We are live on
!
Find out more
Two Sigma Advisers Portfolio holdings
AUM
$51.4B
1-Year Est. Return
31.07%
This Fund
S&P 500
This Quarter
Est. Return
-3%
1 Year Est. Return
+31.07%
3 Year Est. Return
+128.94%
5 Year Est. Return
+161.75%
10 Year Est. Return
+607.04%
AUM
$44.4B
AUM Growth
+$1.2B
(+2.8%)
Cap. Flow
+$3.32B
Cap. Flow
% of AUM
7.48%
Top 10 Holdings %
Top 10 Hldgs %
17.65%
Holding
2,641
New
312
Increased
1,037
Reduced
994
Closed
281
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$519M |
| 2 |
Salesforce
CRM
|
+$460M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$381M |
| 4 |
Boston Scientific
BSX
|
+$347M |
| 5 |
Intuitive Surgical
ISRG
|
+$319M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$555M |
| 2 |
Eli Lilly
LLY
|
+$536M |
| 3 |
Meta Platforms (Facebook)
META
|
+$433M |
| 4 |
Progressive
PGR
|
+$330M |
| 5 |
Lam Research
LRCX
|
+$294M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.86% |
| 2 | Healthcare | 15.38% |
| 3 | Financials | 14.3% |
| 4 | Consumer Discretionary | 11.43% |
| 5 | Industrials | 10.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHR
2326
Braemar Hotels & Resorts
BHR
$165M
| $44.3K | ﹤0.01% |
17,800
-500
| -3% | -$1.36K |
|
2327
AC Immune
ACIU
$231M
| $44.2K | ﹤0.01% |
23,610
+10,200
| +76% | +$25.7K |
|
|
NOTV
2328
DELISTED
Inotiv
NOTV
| $44K | ﹤0.01% |
19,900
-2,600
| -12% | -$9.54K |
|
2329
Air Industries Group
AIRI
$13.1M
| $42.1K | ﹤0.01% |
+12,100
| New | +$49.5K |
|
2330
Arbutus Biopharma
ABUS
$853M
| $41.9K | ﹤0.01% |
12,000
| – | – |
|
|
ADAP
2331
DELISTED
Adaptimmune Therapeutics
ADAP
| $40.7K | ﹤0.01% |
206,732
+135,997
| +192% | +$70.4K |
|
2332
Atossa Therapeutics
ATOS
$23.4M
| $38.3K | ﹤0.01% |
3,793
+966
| +34% | +$11.7K |
|
2333
GEE Group
JOB
$23M
| $38.2K | ﹤0.01% |
+189,200
| New | +$43.4K |
|
|
OGI
2334
Organigram Holdings
OGI
$128M
| $38K | ﹤0.01% |
37,650
-48,368
| -56% | -$64.4K |
|
2335
Telos
TLS
$331M
| $37.8K | ﹤0.01% |
15,900
-6,200
| -28% | -$19K |
|
|
SLRN
2336
DELISTED
ACELYRIN
SLRN
| $37.3K | ﹤0.01% |
15,100
-1,600
| -10% | -$3.8K |
|
2337
Century Therapeutics
IPSC
$368M
| $36.6K | ﹤0.01% |
76,900
+25,900
| +51% | +$19.5K |
|
2338
Planet Labs
PL
$7.09B
| $35.8K | ﹤0.01% |
+10,600
| New | +$49.6K |
|
|
ORGN
2339
DELISTED
Origin Materials
ORGN
| $32.4K | ﹤0.01% |
1,627
-599
| -27% | -$16.5K |
|
|
VIGL
2340
DELISTED
Vigil Neuroscience
VIGL
| $31.9K | ﹤0.01% |
17,900
-51,200
| -74% | -$115K |
|
2341
LG Display
LPL
$2.79B
| $31.7K | ﹤0.01% |
10,200
-300
| -3% | -$976 |
|
2342
Alto Neuroscience
ANRO
$1.04B
| $30.9K | ﹤0.01% |
+14,300
| New | +$51.2K |
|
2343
Tenaya Therapeutics
TNYA
$158M
| $29.5K | ﹤0.01% |
+51,800
| New | +$51.1K |
|
2344
Zevia
ZVIA
$118M
| $28.3K | ﹤0.01% |
+13,100
| New | +$42.9K |
|
|
TE
2345
T1 Energy
TE
$1.02B
| $28.2K | ﹤0.01% |
+22,400
| New | +$41.3K |
|
2346
VistaGen Therapeutics
VTGN
$9.86M
| $26.8K | ﹤0.01% |
10,732
-1,300
| -11% | -$3.68K |
|
2347
Vuzix
VUZI
$179M
| $26.7K | ﹤0.01% |
+13,100
| New | +$42.9K |
|
2348
GrafTech
EAF
$187M
| $24.7K | ﹤0.01% |
2,820
+920
| +48% | +$12K |
|
2349
Ampco-Pittsburgh
AP
$161M
| $23.4K | ﹤0.01% |
10,800
-300
| -3% | -$663 |
|
2350
Bridger Aerospace
BAER
$110M
| $17.4K | ﹤0.01% |
+15,400
| New | +$33.9K |
|
Similar funds
CWM
VRS
FAF
BGIM
CIM
PPFA
Two Sigma Advisers's Q1 2025 Portfolio in Review
As of Q1 2025, Two Sigma Advisers held 2,641 positions worth $44.4B, up 2.8% from $43.2B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Two Sigma Advisers deployed $3.32B of net new capital in Q1 2025, opening 312 new positions and adding to 1,037 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 553,800 shares worth $351M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Visa, an estimated $555M trimmed.
- Two Sigma Advisers's largest Q1 2025 buy was Regeneron Pharmaceuticals: 553,800 shares worth $351M.
- Two Sigma Advisers added most to Broadcom in Q1 2025, an estimated $519M increase.
- Two Sigma Advisers's biggest Q1 2025 reduction was Visa, cutting an estimated $555M.
- Two Sigma Advisers fully exited Abbott in Q1 2025, selling an estimated $158M.
- Two Sigma Advisers's ten largest holdings make up 18% of its $44.4B portfolio in Q1 2025.
- Two Sigma Advisers opened 312 new positions and closed 281 in Q1 2025.
- Two Sigma Advisers's portfolio value rose 2.8% quarter-over-quarter to $44.4B.
Based on Two Sigma Advisers's 13F filing for Q1 2025, filed 15 May 2025.